Nacho Aguilo
Overview
Explore the profile of Nacho Aguilo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvo S, Rodrigo-Munoz J, Tarancon R, Uranga S, Martin C, Del Pozo V, et al.
EBioMedicine
. 2025 Feb;
113:105637.
PMID: 40015173
No abstract available.
2.
Peralta-Alvarez M, Downward K, White A, Azema H, Sibley L, Sarfas C, et al.
NPJ Vaccines
. 2024 Nov;
9(1):230.
PMID: 39567530
The only currently licensed vaccine against tuberculosis (TB), Bacille Calmette Guérin (BCG), is insufficient to control the epidemic. MTBVAC is a live attenuated strain of Mycobacterium tuberculosis (M.tb) and is...
3.
Felgueres M, Esteso G, Aguilo N, Vales-Gomez M
Methods Cell Biol
. 2024 Nov;
190:203-221.
PMID: 39515880
Natural Killer (NK) cells are cytotoxic lymphocytes involved in the recognition of pathogen-infected and cancer cells. NK cells are very attractive as cell therapy tools because they are neither restricted...
4.
Calvo S, Rodrigo-Munoz J, Tarancon R, Uranga S, Martin C, Del Pozo V, et al.
EBioMedicine
. 2024 Aug;
107:105272.
PMID: 39173529
Background: MTBVAC is a live attenuated tuberculosis vaccine, currently undergoing phase III evaluation for tuberculosis prevention. In previous preclinical studies, we found that local pulmonary administration of MTBVAC via the...
5.
Felgueres M, Esteso G, Garcia-Jimenez A, Dopazo A, Aguilo N, Mestre-Duran C, et al.
Sci Rep
. 2024 Jun;
14(1):13133.
PMID: 38849432
The short-lived nature and heterogeneity of Natural Killer (NK) cells limit the development of NK cell-based therapies, despite their proven safety and efficacy against cancer. Here, we describe the biological...
6.
Peralta Alvarez M, Jones H, Azema H, Davis C, White A, Sarfas C, et al.
Front Immunol
. 2024 May;
15:1387454.
PMID: 38799468
Introduction: Mycobacteria are known to exert a range of heterologous effects on the immune system. The mycobacteria-based Freund's Complete Adjuvant is a potent non-specific stimulator of the immune response used...
7.
Minute L, Bergon-Gutierrez M, Mata-Martinez P, Fernandez-Pascual J, Terron V, Bravo-Robles L, et al.
iScience
. 2024 Feb;
27(2):108869.
PMID: 38318361
Trained immunity (TI) represents a memory-like process of innate immune cells. TI can be initiated with various compounds such as fungal β-glucan or the tuberculosis vaccine, Bacillus Calmette-Guérin. Nevertheless, considering...
8.
Moreo E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, Guerrero C, Gomez A, et al.
Nat Commun
. 2023 Oct;
14(1):6090.
PMID: 37794033
Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of...
9.
Esteso G, Felgueres M, Garcia-Jimenez A, Reyburn-Vales C, Benguria A, Vazquez E, et al.
Oncoimmunology
. 2022 Dec;
12(1):2160094.
PMID: 36567803
Bacillus Calmette-Guérin (BCG), the nonpathogenic strain used as tuberculosis vaccine, has been successfully used as treatment for non-muscle invasive bladder cancer for decades, and suggested to potentiate cellular and humoral...
10.
Moreo E, Uranga S, Pico A, Gomez A, Nardelli-Haefliger D, Del Fresno C, et al.
J Immunother Cancer
. 2022 Jul;
10(7).
PMID: 35781395
Background: Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); however, it still fails in a significant proportion of patients, so improved treatment options are urgently needed....